Premier Pharmacy Labs Recalls Neostigmine Methylsulfate Syringes for Sterility Concerns
Premier Pharmacy Labs is recalling Neostigmine Methylsulfate syringes nationwide due to FDA findings of insufficient environmental controls and lack of sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of sterility assurance in a parenteral medication, which poses a significant risk of serious injury or infection.
Plain-English summary
Premier Pharmacy Labs Inc is recalling 4,806 syringes of Neostigmine Methylsulfate, 5mg/5mL (1mg/mL), 5mL Single Dose Syringe. The product is identified by NDC 69623-234-15 and barcode 5 69623 23415 0. The recall covers all lots remaining within their expiry dates.
The recall was initiated following an FDA inspection that identified insufficient environmental controls, potential cross-contamination, and a lack of product-specific process validations. These deficiencies can result in a lack of sterility assurance for the medication.
The affected product was distributed nationwide in the USA. Consumers and healthcare providers should stop using the recalled syringes and contact their pharmacist or healthcare provider for further instructions.
The recalled product
- Product
- Neostigmine Methylsulfate, 5mg/5mL (1mg/mL), 5mL Single Dose Syringe, Rx only, Premier Pharmacy Labs, 8265 Commercial Way, Weeki Wachee, FL 34613, NDC: 69623-234-15, barcode 5 69623 23415 0.
- Manufacturer
- Premier Pharmacy Labs Inc
- Category
- Drug — Injectable Medication
- Affected units
- 4,806
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 18 recalled by Premier Pharmacy Labs Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 18 products in this recall →Related recalls
Same manufacturer · Premier Pharmacy Labs Inc
See all →- SeverePremier Pharmacy Labs Recalls Isoproterenol HCL Bags Due to Sterility Concerns
FDA (Drugs) · 2019-07-03
- SeverePremier Pharmacy Labs Recalls Succinylcholine Chloride Syringes for Sterility Concerns
FDA (Drugs) · 2019-07-03
- SeverePremier Pharmacy Labs Recalls Phenylephrine Injection Due to Sterility Concerns
FDA (Drugs) · 2019-07-03
- SeverePremier Pharmacy Labs Recalls Droperidol Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-07-03
- SeverePremier Pharmacy Labs Recalls Orphenadrine Citrate Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-07-03
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SeverePremier Pharmacy Labs Recalls NeoStigmine Syringes Due to Sterility Concerns
FDA (Drugs) · 2018-05-02
- ModeratePremier Pharmacy Labs Recalls Neostigmine Methylsulfate Syringes Due to Labeling Error
FDA (Drugs) · 2017-12-27
- SeverePremier Pharmacy Labs Recalls Morphine Sulfate Syringes Due to Sterility Concerns
FDA (Drugs) · 2018-05-02
- SevereSCA Pharmaceuticals Recalls Neostigmine Syringes Due to Sterility Concerns
FDA (Drugs) · 2021-01-13
- SevereNeostigmine Methylsulfate Injectable Syringes Recalled for Sterility Assurance
FDA (Drugs) · 2022-02-02
- SeverePremier Pharmacy Labs Recalls Morphine Sulfate Injection Due to Sterility Concerns
FDA (Drugs) · 2018-05-02